Twenty-four hemodialysis patients, 14 with uremic neuropathy and 10 symptom-free, were studied over 12 months. Cuprophan and AN 69 membrane dialyzers were used in their treatment in order to investigate the influence of different membranes on plasma levels of middle molecular weight substances (MMS) and uremic neuropathy. Hemodialysis with the cuprophan membrane caused no significant changes in plasma MMS levels or in the neurological condition of patients. The effect of dialysis with AN 69 membrane depended on initial plasma MMS levels. Initially high plasma MMS levels decreased significantly and significant improvement of neuropathy was achieved. In neuropathic patients with plasma MMS levels similar to those of symptom-free patients, hemodialysis with AN 69 membrane had no effect. These results suggest that hemodialysis with MMS high-permeability membranes may be recommended for neuropathic patients with high plasma MMS levels.
TenckhoffH, ShilipeterG, BoenST. One year's experience with home peritoneal dialysis. Trans Am Soc Artif Intern Organs1965; 11:11–28.
2.
ScribnerBH. Discussion. Trans Am Soc Artif Intern Organs1965; 11:29.
3.
BabbAL, FarrellPC, UvelliDA, ScribnerBH. Hemodialyzer evaluation examination of solute molecular spectra. Trans Am Soc Artif Intern Organs1972; 18:98–105.
4.
DzùrikR, BožekP, RezničekJ, ObornikovaA.Blood level of middle molecular substances during ureamia and haemodialysis. Proc Eur Dial Transplant Assoc1973; 10:263–70.
5.
Funck-BrentanoJ-L, ManN-K, SausseA, Characterization of a 1100–1300 MW uremic neurotoxin. Trans Am Soc Artif Intern Organs1976; 22:163–7.
6.
FürstP, ZimmermanL, BergströmJ.Determination of endogenous middle molecules in normal and uremic body fluids. Clin Nephrol1976; 5:178–88.
7.
DzùrikR, SpustovàV.Metabolic actions of middle molecules. Artif Organs1980; 4 (Suppl):59–62.
8.
BraguerD, GalliceP, MontiJP, MurisascoA, CrevatA.Inhibition of microtubule formation by uremic toxins: action mechanism and hypothesis about the active component. Clin Nephrol1986; 25:212–8.
9.
AsabaH, AlvestrandA, FürstP, BergströmJ.Clinical implications of uremic middle molecules in regular hemodialysis patients. Clin Nephrol1983; 19:179–87.
10.
Funck-BrentanoJ-L, ManN-K, SausseA.Effect of more porous dialysis membranes on neuropathic toxins. Kidney Int1975; 7 (Suppl 2):S52–S57.
11.
BotellaJ, GeaT, Sanz-GuajardoD, CriadoM, TorresMT, GuardiolaJ.Blood levels of middle molecules and their effects on motor nerve conduction velocity. Artif Organs1980; 4(Suppl):151–5.
12.
OulesR, EmondC, BrangerB, MionH, MionC.Middle molecule accumulation in uremia: an “extra uremic factor”?Artif Organs1980; 4(Suppl): 177–83.
13.
ViolonteF., LorenziS, FuselloM.Uremic neuropathy: Clinical and neurophysiological investigation of dialysis patients using different chemical membranes. Eur Neurol1985; 24:398–404.
14.
RingoirA, SmerRDe. Serum chromatographic pattern in different dialysis strategies. Int J Artif Organs1978; 1:218–23.
15.
AsabaH, FürstP, OulèsR, YahielV, ZimmermanL, BergströmJ.The effect of hemodialysis on endogenous middle molecules in uremic patients. Clin Nephrol1979; 11:257–66.
16.
de FremontJF, CoevoetB, MoriniereP, Evaluation of the dialysis adequacy index of Babb (BI) by controlled comparison of 2 strategies of dialysis. Abstracts 8th Int Cong Nephrol Athens1981; DI-027.
17.
MabinD, CabonM, CledesJ, Evolution de la vitesse de conduction nerveuse motrice et du rèflexe d'Hoffmann chez cent dialysès chroniques. Sem Hop Paris1980; 56:15–21.
18.
ValekA, SpustovàV, LopotF, ErbenJ, DzùrikR.Can plasma concentration of middle molecules contribute to assessment of adequate dialysis treatment?Artif Organs1986; 10:37–44.
FaguerP, ManN-K, CueilleG, Funck-BrentanoJ-L. Drug interaction in middle molecule analysis, with special reference to acetylsalicylic acid. Artif Organs1984; 8:226–9.
MilutinovicJ, CutlerRE, HooverP, MeijseB, ScribnerBH. Measurement of residual glomerular filtration rate in patients receiving repetitive hemodialysis. Kidney Int1975;8:185–90.
23.
MilloraAB, WoodruffMW, KileyJE. Comparison of higher blood flow hemodialysis with lower blood flow in light of the square meter hypothesis. Trans Am Soc Artif Intern Organs1972; 18:85–90.
24.
CambiV, Dall'AglioP, SavazziG, ArisiL, RossiE, MigoneL.Clinical assessment of haemodialysis patients with reduced small molecules removal. Proc Eur Dial Transpl Assoc1972; 9:67–71.
25.
ManN-K, CueilleG, ZingraffJ, BoudetJ, SausseA, Funck-BrentanoJ-L. Uremic neurotoxin in the middle molecular weight range. Artif Organs1980; 4:116–20.
26.
GotchFA, SargentJA. Modeling of middle molecules in clinical studies. Artif Organs1980; 4(Suppl): 133–6.
27.
AbikoT, KumikawaM, HiguchH, SekinoH.Identification and synthesis of a heptapeptide in uremic fluid. Biochem Biophys Res Commun1978; 84:184–91.
28.
AbikoT, OnoderaI, SekinoH.Isolation, structures and biological activity of the Trp-containing pentapeptide from uremic fluid. Biochem Biophys Res Commun1979; 89:813–8.
